Corcept Therapeutics Inc. (CORT) Shares Down 1.8%
Corcept Therapeutics Inc. (NASDAQ:CORT) was down 1.8% during trading on Monday . The company traded as low as $5.39 and last traded at $5.40, with a volume of 133,777 shares changing hands. The stock had previously closed at $5.50.
A number of equities research analysts have recently commented on CORT shares. FBR & Co reaffirmed a “buy” rating on shares of Corcept Therapeutics in a research report on Thursday, August 4th. Zacks Investment Research cut Corcept Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, July 28th.
The stock has a market cap of $597.21 million and a PE ratio of 600.00. The firm’s 50-day moving average price is $5.76 and its 200 day moving average price is $5.09.
Corcept Therapeutics (NASDAQ:CORT) last released its earnings results on Tuesday, August 2nd. The company reported $0.03 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.02. The firm earned $19.70 million during the quarter, compared to analyst estimates of $18.36 million. On average, equities analysts forecast that Corcept Therapeutics Inc. will post $0.05 EPS for the current fiscal year.
Corcept Therapeutics Inc is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company’s focus is on those disorders that are associated with a steroid hormone cortisol. Elevated levels and abnormal release patterns of cortisol have been implicated in a range of human disorders.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.